Pharmacogenetics Of Specific Infectious Diseases

Inherited differences in response to anti-infective drugs were observed several decades ago. Indeed, it is in the field of anti-infective therapy that the importance of polymorphisms in drug disposition was first encountered: the N-acetyltransferase 2 (NAT2) acetylation polymorphism discovered during isoniazid treatment of TB patients (5) was one of the first examples of a pharmacogenetic defect influencing drug biotransformation in human populations. A number of antibiotics and chemotherapeutic agents are substrates of polymorphic phases I and II metabolic pathways and transport genes (Table 2). However, there are currently limited data on the clinical relevance of such genetic variations. In the following, we discuss the current pharmacogenetic knowledge relevant to the treatment of four major diseases and infectious syndromes: HIV, TB, malaria, and sepsis.

Population Pathogen

Population Pathogen

Who will he infected? Who will suffer severe disease? Who needs treatment?

Pharmacogenetic determinants

What therapy for maximal efficacy What therapy for minimal toxicity No allergic reaction

Figure 1 Genetic markers in the treatment of infection. Genetic determinants of susceptibility define who should be treated, and pharmacogenetic markers help in the choice of therapy.

Cure Your Yeast Infection For Good

Cure Your Yeast Infection For Good

The term vaginitis is one that is applied to any inflammation or infection of the vagina, and there are many different conditions that are categorized together under this ‘broad’ heading, including bacterial vaginosis, trichomoniasis and non-infectious vaginitis.

Get My Free Ebook


Post a comment